Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Jefferies analysts lowered the price target on Humana (NYSE:HUM) stock to $244.00 from $287.00 on Wednesday ... with insights into the company’s strategic positioning and market performance. This ...

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, ...

A return of a former CEO and questions about its Medicare Advantage pricing dominate the outlook for this formerly ...

The S&P 500 slipped less than 0.1% on Thursday, May 22, after the House narrowly passed the Republicans' "big beautiful" tax ...

Humana (NYSE:HUM) recently reported first-quarter earnings, showcasing a revenue increase from USD 29,611 million to USD 32,112 million and a net income rise from USD 741 million to USD 1,244 million.